Abstract | BACKGROUND: The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long-term statin use and HCC recurrence after surgical resection of hepatitis B virus (HBV)-related HCC. METHODS: Patients who initially underwent curative resection for HBV-related HCC between 2005 and 2015 were recruited and followed up until December 2019. Patients were classified into statin user and non- statin user groups based on whether or not they had been prescribed statins for ≥2 years. The primary outcome was HCC recurrence, and the secondary outcome was liver-related mortality. The cumulative incidence by statin use was estimated using the Kaplan-Meier method and compared using the log-rank test. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression. RESULTS: Among 5653 patients with a median 6.1 years of follow-up, HCC recurrence and liver-related mortality occurred in 1603 and 316 patients, respectively. The 5-year cumulative incidence of HCC recurrence in the statin user group (15.9%) was significantly lower than that in the non-user group (21.3%; p = .019). From multivariable Cox regression analysis, statin use was significantly associated with a reduced risk of HCC recurrence (aHR 0.77, 95% CI: 0.61-0.98; p = .035) and liver-related mortality (aHR 0.48, 95% CI: 0.25-0.90; p = .023). CONCLUSION: Long-term statin use was significantly associated with reduced risk of HCC recurrence and liver-related mortality after curative resection of HBV-related HCC.
|
Authors | Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 53
Issue 4
Pg. e13936
(Apr 2023)
ISSN: 1365-2362 [Electronic] England |
PMID | 36504405
(Publication Type: Journal Article)
|
Copyright | © 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. |
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Topics |
- Aged
- Female
- Humans
- Male
- Middle Aged
- Carcinoma, Hepatocellular
(drug therapy, mortality, pathology, surgery, virology)
- Hepatitis B virus
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Liver Neoplasms
(drug therapy, mortality, pathology, surgery, virology)
- Neoplasm Recurrence, Local
(epidemiology)
- Prognosis
- Risk Assessment
|